SCHEMBL9315754

SCHEMBL9315754

NCC(CC(=O)O)c1cc2cc(Br)ccc2o1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.55
GRIN1 Q05586 1/20 0.48
GRIN2A Q12879 1/20 0.48
GRIN2B Q13224 1/20 0.48
GRIN2C Q14957 1/20 0.48
GPR35 Q9HC97 1/20 0.48
GABBR2 O75899 1/20 0.44
GABBR1 Q9UBS5 1/20 0.44
ALDH1A1 P00352 5/20 0.44
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
MAOA P21397 1/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
CYP2A6 P11509 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9196666 0.84 GABBR2 (0.43) GABBR2GABBR1LMNACA12CA1
SCHEMBL9202393 0.84 GABBR2 (0.54) GPR35GABBR2GABBR1ALDH1A1RAB9A
SCHEMBL9196674 0.84 MAOB (0.47) GABBR2GABBR1LMNACA12CA1
SCHEMBL9203506 0.82 LMNA (0.43) PIM1GABBR2GABBR1LMNACA12
SCHEMBL9198993 0.82 GABBR2 (0.44) GPR35GABBR2GABBR1RAB9ANPC1
SCHEMBL9594099 0.81 PIM1 (0.57) PIM1GABBR2GABBR1MAOALMNA
SCHEMBL9200327 0.79 ALDH1A1 (0.45) ALDH1A1RAB9ASMN1; SMN2CA12CA1
SCHEMBL9195312 0.79 GAA (0.43) GABBR2GABBR1ALDH1A1LMNA
SCHEMBL10966536 0.77 PIM1 (0.50) PIM1GRIN1GRIN2AGRIN2BGRIN2C
SCHEMBL9315751 0.74 GABBR2 (0.41) PIM1GABBR2GABBR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5278166-A 4-amino-3-heteroaryl butyric acid compounds, compositions, and their use for treating disorders involving a dysfunction of GABAB receptors ADIR ET COMPAGNIE (FR) 1994-01-11 US disclosed
US-5214063-A 4-aminobutyric acid compounds, compositions and methods of use for treating disorders related to a dysfunction of GABAB receptors ADIR ET COMPAGNIE (FR) 1993-05-25 US disclosed
US-5162364-A Treatment of spastic and senescence disorders ADIR ET COMPAGNIE (FR) 1992-11-10 US disclosed